Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. BVAXF


Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > Note this part of the nr
View:
Post by frankman on Jun 03, 2022 10:52am

Note this part of the nr

BioVaxys and Ohio State were recently invited by The Coalition for Epidemic Preparedness Innovations ("CEPI") to present their strategy for a pan-sarbecovirus vaccine to a panel of CEPI vaccine experts. Following this presentation, the Company and Ohio State were invited to return and deliver an update following completion of the animal studies. Based in Oslo, London, and Washington, DC, CEPI is a global foundation that directs public, private, and philanthropic funding towards vaccines targeting major unmet needs
Comment by mba123ccu on Jun 03, 2022 11:17am
This seems to augur well for BIOV. If  they can prove to and convince CEPI that they are on track with their research then a recommendation for funding may be available.
Comment by Humanist on Jun 03, 2022 1:38pm
excellent highlight frankman, the fact they invited tem again to get an update shows strong interest and faith in their reserach. and for us investors, means biovayxys has agreat potential of reaching their end goal.. glta 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities